Inhibition of insulin‐like growth factor 2 mRNA‐binding protein 1 sensitizes colorectal cancer cells to chemotherapeutics

Abstract

Abstract Although colorectal cancer (CRC) treatment has seen a remarkable improvement in the recent years, many patients will develop metastasis due to the resistance of cancer cells to chemotherapeutics. Targeting mechanisms driving the resistance of CRC cells to treatment would significantly reduce cases of metastasis and death. Induction of insulin‐like growth factor 2 mRNA‐binding protein 1 (IGF2BP1), a direct target of the Wnt/β‐catenin signaling pathway, might promote resistance of CRC cells to treatment via activation of anti‐apoptotic pathways and induction of the multidrug resistance (MDR1) membrane transporter that pumps drugs out of the cells. We hypothesized that inhibition of IGF2BP1 will sensitize CRC cells to chemotherapeutics. We used CRC cell lines with different status of activation of Wnt signaling to show that inhibition of IGF2BP1 potentiates the anti‐growth and anti‐proliferative effects of chemotherapeutics on CRC cells with activated Wnt/β‐catenin signaling pathway. We observed that the inhibition of IGF2BP1 significantly increases apoptosis in the same cells. A remarkable reduction in the migratory capability of those cells was noted as well. We found that inhibition of IGF2BP1 is sufficient to decrease the resistance of chemotherapy‐resistant cancer cells with activated Wnt/β‐catenin signaling pathway. These findings portray IGF2BP1 as a good candidate for CRC therapy.

Keywords

• 5‐FU
• chemotherapeutics
• CRC
• IGF2BP1
• irinotecan
• oxaliplatin